Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers
Top Cited Papers
Open Access
- 7 January 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Abstract
Self-replicating RNA (srRNA) technology, in comparison to mRNA vaccines, has shown dose-sparing by approximately 10-fold and more durable immune responses. However, no improvements are observed in the adverse events profile. Here, we develop an srRNA vaccine platform with optimized non-coding regions and demonstrate immunogenicity and safety in preclinical and clinical development. Optimized srRNA vaccines generate protective immunity (according to the WHO defined thresholds) at doses up to 1,000,000-fold lower than mRNA in female mouse models of influenza and rabies. Clinically, safety and immunogenicity of RBI-4000, an srRNA vector encoding the rabies glycoprotein, was evaluated in a Phase I study (NCT06048770). RBI-4000 was able to elicit de novo protective immunity in the majority of healthy participants when administered at a dose of 0.1, 1, or 10 microgram (71%, 94%, 100%, respectively) in a prime-boost schedule. Similarly, we observe immunity above the WHO benchmark of protection following a single administration in most participants at both 1 and 10 microgram doses. There are no serious adverse events reported across all cohorts. These data establish the high therapeutic index of optimized srRNA vectors, demonstrating feasibility of both low dose and single dose approaches for vaccine applications.Keywords
This publication has 64 references indexed in Scilit:
- Requirements at the 3′ End of the Sindbis Virus Genome for Efficient Synthesis of Minus-Strand RNAJournal of Virology, 2005
- A Mouse Model for the Evaluation of Pathogenesis and Immunity to Influenza A (H5N1) Viruses Isolated from HumansJournal of Virology, 1999
- Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAsJournal of Virology, 1993
- Sindbis Virus: An Efficient, Broad Host Range Vector for Gene Expression in Animal CellsScience, 1989
- The Effect of Interferon Treatment in Rabies Prophylaxis in Immunocompetent, Immunosuppressed, and Immunodeficient MiceJournal of Interferon Research, 1987
- DETERMINANTS OF IMMUNITY TO INFLUENZA INFECTION IN MANBritish Medical Bulletin, 1979
- Replication of sindbis virus VI. Poly(A) and poly(U) in virus-specific RNA speciesVirology, 1978
- A rapid reproducible test for determining rabies neutralizing antibody.1973
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesEpidemiology and Infection, 1972
- EVALUATION OF MONOVALENT INFLUENZA VACCINESAmerican Journal of Epidemiology, 1952